Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
-First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted …